Coherus And AbbVie Trade Legal Blows Amid Radical Adalimumab Price Offering
PBM SmithRx Works With Mark Cuban’s Firm To Offer Biosimilar At More Than 90% Off
Coherus BioSciences’ plans earlier this month to launch its Humira biosimilar, Yusimry, at a massive discount have sparked both a legal battle and an arrangement with a “next generation” pharmacy benefit manager.
